Detection Of Uterine Cancer Research Articles

Detection of uterine cancer biomarker EGFR through an aptasensor utilizing a carbon electrode modified with silver nanowires

Treatment options and survival chances are enhanced with early detection of uterine cancer. In this work, an electrochemical paper analytical device (ePAD) for detecting Epidermal growth factor receptor (EGFR), a biomarker for uterine cancer, was demonstrated. The objective of this study is to develop a rapid nano-biosensing method for early detection of fatal uterine cancer. The proposed ePAD is inexpensive, disposable, easy, and repeatable, among other advantageous qualities. The ePAD's Working electrode comprises of silver nanowires. In addition, the use of aptamers has enhanced the performance of the biosensor. The silver nanowires' morphological, optical, elemental content, and phase characteristics were assessed by employing several analytical techniques: transmission electron microscopy (TEM), Fourier transform infrared (FTIR), Scanning electron microscopy (SEM), X-ray diffraction (XRD), and UV–vis spectroscopy. This aptamer-modified ePAD assists in amplifying the signal of the developed platform to identify EGFR. The biosensor utilized the voltametric detection of EGFR in a solution of 0.5 mM potassium ferro/ferri cyanide, which acts as a redox pair by applying a potential of 50 mV/s at the working electrode yielded the highest performance. The designed sensor demonstrated an optimum response broad linearity of 0.01 ng/ml – 1 μg/ml for EGFR, with limit of detection (LOD) of 0.01ng/ml.

Performance of the WID-qEC test versus sonography to detect uterine cancers in women with abnormal uterine bleeding (EPI-SURE): a prospective, consecutive observational cohort study in the UK

To detect uterine cancer, simpler and more specific index tests are needed to triage women with abnormal uterine bleeding to a reference histology test. We aimed to compare the performance of conventional index imaging tests with the novel WID-qEC DNA methylation test in terms of detecting the presence or absence of uterine cancers in women with abnormal uterine bleeding. EPI-SURE was a prospective, observational study that invited all women aged 45 years and older with abnormal uterine bleeding attending a tertiary gynaecological diagnostic referral centre at University College London Hospital (London, UK) to participate. Women meeting these inclusion criteria who consented to participate were included. Pregnant women and those with previous hysterectomy were excluded. A cervicovaginal sample for the WID-qEC test was obtained before standard assessment using index imaging tests (ie, ultrasound) and, where applicable, reference histology (ie, biopsy, hysteroscopy, or both) was performed. Technicians performing the WID-qEC test were masked to the final clinical outcome. The result of the WID-qEC test is defined as the sum of the percentage of fully methylated reference (ΣPMR) of the ZSCAN12 and GYPC regions. Patients were followed until diagnostic resolution or until June 12, 2023. The primary outcome was to assess the real-world performance of the WID-qEC test in comparison with ultrasound with regard to the area under the receiver-operating-characteristic curve (AUC), sensitivity, specificity, and positive and negative predictive values. EPI-SURE is registered with ISRCTN (16815568). From June 1, 2022, to Nov 24, 2022, 474 women were deemed eligible to participate. 74 did not accept the invitation to participate, and one woman withdrew after providing consent. 399 women were included in the primary analysis cohort. Based on 603 index imaging tests, 186 (47%) women were recommended for a reference histology test (ie, biopsy, hysteroscopy, or both). 12 women were diagnosed with cancer, 375 were not diagnosed with cancer, and 12 had inconclusive clinical outcomes and were considered study dropouts. 198 reference histology test procedures detected nine cases of cancer and missed two; one further cancer was directly diagnosed at hysterectomy without a previous reference test. The AUC for detection of uterine cancer based on endometrial thickness in mm was 87·2% (95% CI 71·1-100·0) versus 94·3% (84·7-100·0) based on WID-qEC (p=0·48). Endometrial thickness assessment on ultrasound scan was possible in 379 (95%) of the 399 women and a prespecified cut-off of 4·5 mm or more showed a sensitivity of 90·9% (95% CI 62·3-98·4), a specificity of 79·1% (74·5-82·9), a positive predictive value of 11·8% (6·5-20·3), and a negative predictive value of 99·6% (98·0-99·9). The WID-qEC test was possible in 390 (98%) of the 399 patients with a sensitivity of 90·9% (95% CI 62·3-98·4), a specificity of 92·1% (88·9-94·4), a positive predictive value of 25·6% (14·6-41·1), and a negative predictive value of 99·7% (98·3-99·9), when the prespecified threshold of 0·03 ΣPMR or more was applied. When a higher threshold (≥0·3 ΣPMR) was applied the specificity increased to 97·3% (95% CI 95·1-98·5) without a change in sensitivity. The WID-qEC test delivers fast results and shows improved performance compared with a combination of imaging index tests. Triage of women with abnormal uterine bleeding using the WID-qEC test could reduce the number of women requiring histological assessments for identification of potential malignancy and specifically reduce the false positive rate. The Eve Appeal, Land Tirol, and the European Research Council under the European Union's Horizon 2020 Research and Innovation Programme.

Cancer-associated gene analysis of cervical cytology samples and liquid-based cytology significantly improve endometrial cancer diagnosis sensitivity.

To the best of our knowledge, there are no useful screening methods for early detection of endometrial cancer in asymptomatic individuals. The present study evaluated the usefulness of genetic analysis of liquid-based cytology (LBC) specimens by assessing whether pathological genetic mutations detected in cancer tissue sections were detected in LBC specimens from the cervix and uterus. The primary endpoint was genetic analysis of cervical cytology specimens and LBC for the detection of endometrial cancer. Endometrial thickening (>11 mm) assessed using transvaginal ultrasonography was present in 60% of cases and adenocarcinoma assessed using cervical cytology was present in 50% of cases. In 70% of cases, pathogenic mutations detected in cancer tissue sections were also detected in cervical and/or endometrial LBC specimens. The pathogenic variants identified were PTEN in four cases, tumor protein P53, PI3K catalytic subunit α and fibroblast growth factor receptor 2 in two cases each and APC regulator of WNT signaling pathway, KRAS and catenin β1 in one case each. In the present study, a combination of endometrial thickening assessed by transvaginal ultrasonography, cervical cytology and genetic analysis resulted in a high sensitivity of 90% for detection of endometrial cancer. The combination of these tests is more expensive than conventional methods, but delayed detection of uterine cancer requires multidisciplinary treatment, which increases healthcare costs. Increased spending on early detection of uterine cancer is better economically and may improve patient quality of life.

The rising rates of uterine cancer in Hispanic women of reproductive age in the United States (444)

Objectives: To determine the rate of uterine cancer in reproductive- age Hispanic women compared to non-Hispanic White women and assess trends in obesity associated with uterine cancer in the United States (US). Methods: Data were obtained from the United States Cancer Statistics (USCS) database and the Behavioral Risk Factors Surveillance System (BRFSS) survey from 2001-2018. Obesity-related cancers as classified by the Centers for Disease Control and Prevention (CDC) were described using SEER*Stata. The average annual percent change (AAPC) was calculated using Joinpoint regression. Incidence rates and demographic factors, including age (divided into 5-10 year age groups), sex, and race, were reported. Reproductive age was defined as women under 50 years, whereas young reproductive age was defined as 18-40 years. Results: Over the 17-year study period, 843,116 patients were diagnosed with uterine cancer, with reproductive-age women accounting for 12.7% of cases. In 2018, Hispanic women aged 35-39 years had the highest incidence of uterine cancer among young reproductive- age women at 13.9 (per 100,000), a rate which was 49% higher than White women (9.3 per 100,000). Incidence increased annually at a rate of 4.0 to 4.5% in Hispanic women versus only 1.5 to 2.3% in White women, a nearly two-fold higher rate in this young cohort (25-39 years old). The intersection of young (35-39 years old) Hispanic women residing in the West had an incidence of 14.93 compared to 6.61 (per 100,000) for White women (1.5-fold higher rate), with corresponding annual rates of increase of 5.24% and 1.48%, respectively. Using a predictive model with the current rate of increase, we demonstrated that the incidence of uterine cancer in young (35-39 year old) Hispanic women in the West will be three times that of White women in the next five years (22.4 vs 7.4 per 100,000 by the year 2026). Using the BRFSS survey, Hispanic women aged 35-44 years reported an obesity rate of 30.1% in the year 2018. In a trend analysis from 2001 to 2018, the rate of obesity in Hispanic women rose by 1 .4% annually. Conclusions: The incidence of uterine cancer is rising rapidly in young reproductive-age Hispanic women compared to White women. These results may have public health implications towards the prevention and early detection of uterine cancer in this high-risk population. Objectives: To determine the rate of uterine cancer in reproductive- age Hispanic women compared to non-Hispanic White women and assess trends in obesity associated with uterine cancer in the United States (US). Methods: Data were obtained from the United States Cancer Statistics (USCS) database and the Behavioral Risk Factors Surveillance System (BRFSS) survey from 2001-2018. Obesity-related cancers as classified by the Centers for Disease Control and Prevention (CDC) were described using SEER*Stata. The average annual percent change (AAPC) was calculated using Joinpoint regression. Incidence rates and demographic factors, including age (divided into 5-10 year age groups), sex, and race, were reported. Reproductive age was defined as women under 50 years, whereas young reproductive age was defined as 18-40 years. Results: Over the 17-year study period, 843,116 patients were diagnosed with uterine cancer, with reproductive-age women accounting for 12.7% of cases. In 2018, Hispanic women aged 35-39 years had the highest incidence of uterine cancer among young reproductive- age women at 13.9 (per 100,000), a rate which was 49% higher than White women (9.3 per 100,000). Incidence increased annually at a rate of 4.0 to 4.5% in Hispanic women versus only 1.5 to 2.3% in White women, a nearly two-fold higher rate in this young cohort (25-39 years old). The intersection of young (35-39 years old) Hispanic women residing in the West had an incidence of 14.93 compared to 6.61 (per 100,000) for White women (1.5-fold higher rate), with corresponding annual rates of increase of 5.24% and 1.48%, respectively. Using a predictive model with the current rate of increase, we demonstrated that the incidence of uterine cancer in young (35-39 year old) Hispanic women in the West will be three times that of White women in the next five years (22.4 vs 7.4 per 100,000 by the year 2026). Using the BRFSS survey, Hispanic women aged 35-44 years reported an obesity rate of 30.1% in the year 2018. In a trend analysis from 2001 to 2018, the rate of obesity in Hispanic women rose by 1 .4% annually. Conclusions: The incidence of uterine cancer is rising rapidly in young reproductive-age Hispanic women compared to White women. These results may have public health implications towards the prevention and early detection of uterine cancer in this high-risk population.

Clear Cell Carcinoma of the Uterine Cervix Arising from an Interstitial Cyst Complicated with Endometriosis: A Case Report

Clear cell carcinoma (CCC) of the uterine cervix is rare, and its etiology is unclear, except for reports of prenatal diethylstilbestrol (DES) exposure. In this case report of a 78-year-old postmenopausal Japanese woman with pelvic endometriosis, cervical CCC presented as a deep interstitial tumor, strongly suggesting the patient suffered from cervical endometriosis for a long time. A cystic lesion without solid components was detected in the uterine cervix. Although the patient had regular gynecological examinations every 6 months, she presented 5 years later with a complaint of watery vaginal discharge. Ultrasonography and magnetic resonance imaging (MRI) detected a uterine cervical cystic mass with a solid component. Although no malignancy was confirmed preoperatively, surgery was performed under a high suspicion of cervical cancer. Intraoperative pathology revealed CCC in a solid tumor, so debulking surgery, including lymphadenectomy, was done. Endometrial tissue was found adjacent to the tumor, strongly suggesting the tumor arose from cervical endometriosis. Because endometriosis in ectopic sites carries a risk of carcinogenesis, as is the case in ovarian endometriosis, it may be recommended that a cervical cystic lesion with pelvic endometriosis should be followed up regularly for the early detection of uterine cancer.

Labeling of Anti-SAS1B with Zirconium-89 as a Novel Immune-PET Probe for Uterine Cancer Imaging

Overexpression of Sperm Acrosomal SLLP1 Binding protein (SAS1B) in various cancer types, including uterine cancer cells, was discovered a few years ago, and different monoclonal antibodies (anti-SAS1B) that specifically bind to SAS1B antigens were developed. Labeling of these antibodies with radionuclides can provide an opportunity for imaging and radioimmunotherapy. The objective of this study was to label anti-SAS1B (SB5) with Zirconium-89 (89Zr) for PET imaging and determine its biodistribution. Anti-SAS1B (SB5) antibody was labeled with 89Zr indirectly using the chelator desferrioxamine B (DFO), which is currently a best linker for 89Zr. The antibody, SB5, was first conjugated to DFO with a ratio of 1:5 and then labeled with 250 μCi of 89Zr. Results of PET imaging in mouse-bearing uterine cancer tumor showed a limited uptake. The bio-distribution study matched the PET imaging and confirmed the uptake by the tumor, and the accumulation in bones. In conclusion, labeling of anti-SAS1B could provide an effective way of uterine cancer detection and treatment progression.

Cobertura de detección de cáncer de células uterinas en una región de alta incidência.


 
 
 
 
 OBJETIVO: Analice la cobertura de un programa de detección de cáncer uterino en una ciudad con una alta incidencia de enfermedades, además de los factores asociados con el cumplimiento del programa preventivo actual.
 MÉTODOS: Se realizó un estudio transversal basado en encuestas de hogares. La muestra estaba compuesta por mujeres entre 25 y 59 años de la ciudad de Boa Vista, RR, norte de Brasil, que estaban cubiertas por el programa de detección de cáncer uterino. Se utiliza el método de movimiento por grupos. La variable dependiente fue la participación en un programa de salud de la mujer, definido como menos de una prueba de Papanicolaou en los 36 meses previos a la entrevista; Las variables explicativas se extraen de los datos individuales. Se utilizó un modelo lineal generalizado.
 RESULTADOS: Se analizaron 603 mujeres, con una edad promedio de 38.2 años (DE = 10.2). Se agregaron cinco mujeres diferentes al problema de detección, y la prevalencia de adherencia en los últimos tres años fue de hasta 85.7% (IC 95%: 82.5; 88.5). Un alto ingreso por persona y una consulta médica reciente si se asocia con el menú no se probaron en análisis multivariado. La ignorancia de la enfermedad, las causas y los métodos de prevención se correlacionan con las posibilidades de incumplimiento del sistema de detección; Se informó que el 20.0% de las mujeres estaban involucradas en problemas de detección oportunistas y no rutinarios.
 CONCLUSIONES: El nivel de cobertura reportado es alto, excediendo el nivel recomendado para el control del cáncer cervical. El programa preventivo parece ser de naturaleza oportunista, particularmente para las mujeres más vulnerables (con bajos ingresos y poca información sobre la enfermedad). Los estudios sobre la calidad diagnóstica de la citología cervicovaginal y los calendarios terapéuticos para casos positivos son necesarios para comprender las barreras para el control del cáncer cervical.
 
 
 
 

Acceptability of self-taken vaginal for early detection of HPV DNA in women with limited access to health services: An alternative to increase the coverage in a state of the Mexican Republic

Objective: To determine the acceptability of self-taken vaginal to detect HPV DNA in women living in marginalized areas as an alternative to increase the coverage of health services. Methods: A cross-sectional study from March 2009 to April 2011 in 20 municipalities with the highest marginalization in the Huasteca Region of the State of San Luis Potosi, México. We applied a non-probabilistic quota sampling, which was composed of 608 women aged 25 years and more. The recruitment of women was performed through loudspeakers, leaflets and community meetings. A survey consisted of two sections: socio-demographic data and risk factors, which was validated by construct. We checked the reliability by Cronbach’s Alpha (0.90). Acceptability was determined by considering three indicators: perceived comfort, acceptability of the test and the reasons of acceptability. Results: 41.4% of this woman had 31-40 years. 70.5% were married. 35.3% finished high school and 6.7% had not education experience. 67.4% began their sexual life at 18 years or younger. 85.5% preferred self-collection and 14.5% Pap. These results show a clear acceptability of self-making on the other screening method. Regarding the reason for the preference is that 99.4% of women prefer self-take because they feel more comfortable compared to 0.6% who prefer the Papanicolaou. On the perception of comfort 91% mentioned feel very comfortable with self-making compared with 9% of Pap. There was a statisti cally significant correlation between preference reasons that women have to choose the screening test and the perception of comfort (X2p = 0.000). Conclusions: The self-taken vaginal HPV DNA detection is a well accepted method in women who live in marginalized areas; therefore, it is an alternative that can be considered in the uterine cancer detection testing program.

Diagnostik maligner Tumoren des Uterus durch transabdominale Sonographie: Eine Utopie?

Two hundred non-pregnant women with suspected uterine disease were included in a prospective study designed to assess the accuracy of sonography in conforming or excluding the presence of uterine cancer. All patients were operated on and the preoperative sonographic findings were compared with the final histological diagnosis. The predictive value of sonographic evidence of malignancy was 43.9% (18/41), the predictive value of benign disease was 94.8% (147/155). Sensitivity was 66.7% (18/27) and specificity 85% (147/173). The sonographic detection of uterine cancer is in need of improvement. At present it cannot be used as a substitute of invasive diagnostic tools in patients with suspected uterine cancer.

Erica Wachtel Lecture of Mice & Women

Diagnostic cytology of the female genital tract was introduced almost simultaneously by Aurel Babes in Bucharest, and George Papanicolaou in New York, in 1928. However, neither of these seminal observations made any immediate major clinical impact, and it was not until Papanicolaou and Traut's later published works on uterine cancer detection in the 1940’s, that any momentum was really gained.George Papanicolaou was neither a pathologist nor a gynaecologist. He was an anatomist, and the original Pap smear was designed to assess the hormonal status of mice. However, womankind eventually somehow replaced the mice, and modern exfoliative cytology was born, and the face of cervical cancer management was changed forever.My talk will be scroll through the history of cervical cancer prevention in Britain from 1960 until now, and will be based for the most part on my personal experiences and observations of 36 years before the mast in the Department of Gynaecology and Obstetrics at Birmingham University, and my brushes with some of the past and present Pioneers of the cytology screening programme in the UK, especially in those early years.

Diferencias sociales de la detección oportuna de cáncer cérvico uterino en las mujeres trabajadoras de una universidad de la ciudad de México

In Mexico, cervical uterine cancer (CUC) is one of the leading causes of death among women, however a low degree of participation in the early detection programs has been found. This study is aimed at describing the social determinants of knowledge related to cervical uterine cancer and proper testing being conducted by establishing the social differences with regard thereto among a population of female employees at a public university in Mexico. An analytical cross-sectional study was made. During the March-April 2003 period, a survey was conducted of a representative sample of the female employees who were working at a public university (n=228), 110 of whom were professors (PF) and 118 administrative staff (AS). This population was chosen due to the major socioeconomic differentiation thereof in terms of their job positions (PF versus AS), thus affording the possibility of evaluating the bearing social inequality has on health-related behavior. The survey explored three aspects: living conditions, knowledge of CUC and of proper cervical uterine cancer detection testing. The female professors showed higher levels of income,schooling and knowledge of CUC and of cervical uterine cancer detection testing than the administrative staff. Income and schooling were positively related to the knowledge regarding cervical uterine cancer, cervical uterine cancer detection testing being related to the latter. Socioeconomic inequality among the women studied was reflected in differences in the degree of knowledge and in cervical uterine cancer detection testing being undergone. These differences are associated, above all, to the differences in the level of schooling.

Screening for Gynecologic Cancer

Screening for cancer of the uterus, cervix, and ovary allows earlier detection of disease in some asymptomatic women. The screening tests commonly used have low false-negative rates and, with the exception of endometrial biopsy and endometrial washings in detection of uterine cancer, they have high false-positive rates. Conclusions concerning effectiveness of screening tests in improving the likelihood of a favorable outcome are difficult because there are no randomized trials. Without randomized trials, cost-benefit analysis of screening for gynecologic malignancies is imprecise.

Experience with the EndoPap device for the cytologic detection of uterine cancer and its precursors: A comparison of the EndoPap with fractional curettage or hysterectomy

Cytologic assessment of the endometrium with the EndoPap sampler was compared with curettage or hysterectomy in 249 women with symptoms. The sensitivities for the detection of primary corpus cancer and hyperplasia were 0.90 (59/66) and 0.58 (18/31), respectively. All six cases of atypical endometrial hyperplasia were detected by the EndoPap device. Malignant EndoPap cytologic findings were present In 4 of 10 patients with a primary adnexal malignancy and normal endometrial histologic findings. Ninety-two percent of primary uterine cervical cancers were detected by EndoPap cytologic sampling. The specificity for the cytologic diagnosis of benign conditions was 0.93. EndoPap cytologic sampling has a reasonably high sensitivity for the detection of uterine cancers and preinvasive endometrial lesions with a high risk of progression to carcinoma. Further evaluation as to its usefulness in a screening program for uterine and adnexal cancers in postmenopausal women should be considered.

Experience with the endo-pap device for the cytological detection of uterine cancer and its precursors: A comparison of the endopap sampler with fractional curettage/hysterectomy

Experience with the endo-pap device for the cytological detection of uterine cancer and its precursors: A comparison of the endopap sampler with fractional curettage/hysterectomy

Analytical Report Concerning the Present and Future Development of Uterine Cancer Detection Using Cytology (Mailing Smear Method) at Osaka Medical Association

Analytical Report Concerning the Present and Future Development of Uterine Cancer Detection Using Cytology (Mailing Smear Method) at Osaka Medical Association

DETECTION OF UTERINE CANCER RESULTS OF A COMMUNITY PROGRAM OF 17 YEARS

The Toledo Community Program for the detection of uterine cancer is described and an analysis is presented of the results, 1947–1963. The results indicate the success of a self-supporting community program conducted by practicing physicians from their own offices. The Program has encompassed more than two thirds of the women, 30 or more years old in Lucas County, Ohio. It has resulted in a large decrease in invasive cancer of the uterus. Survival rates following diagnosis of invasive cancer of the uterus are superior to those usually seen.

Detection of uterine cancer. High and low risk groups

Detection of uterine cancer. High and low risk groups

Detection of uterine cancer. Results of a community program of 17 years.

The Toledo Community Program for the detection of uterine cancer is described and an analysis is presented of the results, 1947–1963. The results indicate the success of a self-supporting community program conducted by practicing physicians from their own offices. The Program has encompassed more than two thirds of the women, 30 or more years old in Lucas County, Ohio. It has resulted in a large decrease in invasive cancer of the uterus. Survival rates following diagnosis of invasive cancer of the uterus are superior to those usually seen.

Uterine Cancer Detection With Self-Obtained Cytological Specimens: A Progress Report

Uterine Cancer Detection With Self-Obtained Cytological Specimens: A Progress Report

6-Phosphogluconate dehydrogenase in uterine cancer detection

6-Phosphogluconate dehydrogenase in uterine cancer detection